<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573322</url>
  </required_header>
  <id_info>
    <org_study_id>100-303</org_study_id>
    <nct_id>NCT04573322</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects</brief_title>
  <official_title>Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diffusion Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diffusion Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of TSC as a treatment for participants who are&#xD;
      infected with SARS-CoV-2 (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial has two phases. The first phase is an open-label, pharmacokinetic,&#xD;
      pharmacodynamic, ascending dose, safety and tolerability lead-in. The second phase is a&#xD;
      single-center, randomized, placebo-controlled, double-blind, adaptive, safety and efficacy,&#xD;
      pilot.&#xD;
&#xD;
      The lead-in phase will study 4 doses of TSC and enroll 24 participants. Each TSC dose will be&#xD;
      administered as an IV bolus injection to 6 unique participants per dose level administered&#xD;
      four times per day (every 6 hours) for 5 days. Participants will be assigned in groups of 3,&#xD;
      and a Safety Monitoring Committee (SMC) will review Dose Limiting Toxicities (DLTs) after&#xD;
      each group of 3 participants. The first group of 3 participants will receive TSC at a dose of&#xD;
      0.25 mg/kg. If there are no DLTs, 3 additional subjects will be studied at 0.25 mg/kg. If&#xD;
      there are 0 or 1 DLT among the 6 participants studied at 0.25mg/kg, 3 additional participants&#xD;
      will be studied at the next higher dose, 0.5 mg/kg. If there are no DLTs an additional 3&#xD;
      participants will be studied at 0.5 mg/kg. If there are 0 or 1 DLTs among the 6 subjects&#xD;
      studied at 0.5 mg/kg, 3 additional participants will be studied at the next higher dose, 1.0&#xD;
      mg/kg. The study will continue in this fashion seeking an observed toxicity rate that is &lt;&#xD;
      0.33 among 6 participants at any one dose level, or TSC at 1.5 mg/kg proves to be safe and&#xD;
      tolerable.&#xD;
&#xD;
      As participants complete the initial 5 days of treatment they will continue at their assigned&#xD;
      TSC dose four times per day (every 6 hours) for up to 15 days. Participants will be assigned&#xD;
      to dose levels in ascending order. The dose range is as follows.&#xD;
&#xD;
        -  0.25 mg/kg TSC + Standard of Care&#xD;
&#xD;
        -  0.50 mg/kg TSC + Standard of Care&#xD;
&#xD;
        -  1.00 mg/kg TSC + Standard of Care&#xD;
&#xD;
        -  1.50 mg/kg TSC + Standard of Care&#xD;
&#xD;
      At the completion of the lead-in the Safety Monitoring Committee (SMC) will examine the&#xD;
      resultant safety and blood oxygenation (S:F) data for all participants and determine the&#xD;
      optimum, safe and tolerable dose of TSC for use in the pilot study.&#xD;
&#xD;
      Dose Limiting Toxicity (DLT) is defined as any study drug related grade 3 or 4 adverse event&#xD;
      during the treatment period, with the exception of pulmonary events in the CTCAE that are&#xD;
      known complications of SARS-CoV-2 infection: Acute Respiratory Distress Syndrome (ARDS),&#xD;
      Cough, Dyspnea, Hypoxia, Pneumonitis, Pulmonary Edema, Respiratory Failure, or Respiratory,&#xD;
      Thoracic and Mediastinal disorders - Other. The SMC will apply clinical judgement in their&#xD;
      review of adverse events (particularly abnormal laboratory results).&#xD;
&#xD;
      The two arm, randomized pilot will enroll up to 200 participants, and will be overseen by a&#xD;
      Data Safety Monitoring Board (DSMB). TSC dosing will be at the selected optimum, safe and&#xD;
      tolerable biologic dose with an active to placebo ratio of 2:1 toward providing the maximum&#xD;
      potential benefit to participants. If two doses of TSC are to be studied in the randomized&#xD;
      pilot the active to placebo ratio will be 2:2:1. Randomization will be stratified by disease&#xD;
      severity, age and presence of pre-specified comorbidities. The treatment arms are as follows.&#xD;
&#xD;
        -  TSC + Standard of Care&#xD;
&#xD;
        -  Placebo + Standard of Care&#xD;
&#xD;
      Each TSC dose will be administered as an IV bolus injection 4 times per day (every 6 hours)&#xD;
      for up to 15 days. Participants randomized to placebo will receive an IV bolus injection of&#xD;
      an equivalent volume by participant weight of Normal Saline four times per day (every 6&#xD;
      hours) for up to 15 days.&#xD;
&#xD;
      All study drug administration will be performed by unblinded medical staff. Participants,&#xD;
      investigators and caregivers will not see the injection or injection site or be aware of&#xD;
      randomization.&#xD;
&#xD;
      Blood oxygenation will be measured via recorded continuous pulse oximetry and the&#xD;
      SpO2:Fraction of Inspired Oxygen (FiO2) ratio calculated.&#xD;
&#xD;
      All participants will undergo safety and efficacy assessments including laboratory assays,&#xD;
      blood sampling on days 1 through day 15 (while hospitalized) and day 29 by return clinic&#xD;
      visit or if still hospitalized.&#xD;
&#xD;
      All participants, whether a part of the lead-in phase or randomized pilot, will be assessed&#xD;
      for survival, serious adverse events and adverse events by requested return to the clinic on&#xD;
      Day 60.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Actual">April 29, 2021</completion_date>
  <primary_completion_date type="Actual">March 17, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, pharmacokinetic, pharmacodynamic, ascending dose, safety and tolerability lead-in Single-center, randomized, placebo-controlled, double-blind, adaptive, safety and efficacy pilot</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Lead-in: no masking. Randomized pilot: The participants, care providers, investigators, and outcomes assessors are masked. The pharmacist, unblinded clinical research associate, and unblinded study drug administrator are not masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Up to 70 days post-study drug administration</time_frame>
    <description>Lead-in phase: Overall summary of subjects with TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Recovery Through Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Lead-in phase: Time to achieve (and maintain through Day 28) a World Health Organization (WHO) ordinal COVID-19 severity scale score of 1, 2 or 3 with a minimum 1-point improvement from baseline. The scale assesses clinical status and the range is 0-8, as follows:&#xD;
0. Uninfected - No clinical or virological evidence of infection&#xD;
Ambulatory - No limitation of activities&#xD;
Ambulatory - Limitation of activities&#xD;
Hospitalized, Mild Disease - Hospitalized, no oxygen therapy&#xD;
Hospitalized, Mild Disease - Oxygen by mask or nasal prongs&#xD;
Hospitalized Severe Disease - Non-invasive ventilation or high-low oxygen&#xD;
Hospitalized Severe Disease - Intubation and mechanical ventilation&#xD;
Hospitalized Severe Disease - Ventilation + additional organ support (pressors, Renal Replacement Therapy (RRT), Extracorporeal Membrane Oxygenation (ECMO)&#xD;
Dead - Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WHO Ordinal Severity Scale as a Categorical Improvement or Worsening</measure>
    <time_frame>7 days</time_frame>
    <description>Lead-in phase: Number and percentage of patients by WHO Severity Scale change from baseline through Day 7&#xD;
World Health Organization (WHO) Ordinal Severity Scale&#xD;
Not hospitalized, no limitations on activities&#xD;
Not hospitalized, limitation on activities&#xD;
Hospitalized, no requiring supplemental oxygen&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, on non-invasive ventilation or high flow O2&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation - Ventilator Free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Lead-in phase: Ventilator free days in the first 28 days (to day 29).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>28 days</time_frame>
    <description>Lead-in phase: Days of treatment during the inpatient period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation - Time to Return to Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>Lead-in phase: Time to return to room air or baseline oxygen requirement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation - Pulse Oximetry</measure>
    <time_frame>Baseline through Day 10</time_frame>
    <description>Lead-in phase: Blood oxygenation by recorded continuous pulse oximetry (SpO2:FiO2 ratio)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>SARS-CoV-2 (Covid19)</condition>
  <arm_group>
    <arm_group_label>Lead-in 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead-in 0.50 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead-in 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead-in 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Active TSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trans Sodium Crocetinate</intervention_name>
    <description>TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
    <arm_group_label>Lead-in 0.25 mg/kg</arm_group_label>
    <arm_group_label>Lead-in 0.50 mg/kg</arm_group_label>
    <arm_group_label>Lead-in 1.0 mg/kg</arm_group_label>
    <arm_group_label>Lead-in 1.5 mg/kg</arm_group_label>
    <arm_group_label>Randomized Active TSC</arm_group_label>
    <other_name>TSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days</description>
    <arm_group_label>Randomized Placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride (NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized subjects with confirmed SARS-CoV-2 infection and hypoxemia, defined as&#xD;
             SpO2 &lt; 94% on room air or requiring supplemental oxygen&#xD;
&#xD;
          2. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or&#xD;
             public health assay in any specimen &lt; 72 hours prior to enrollment.&#xD;
&#xD;
          3. WHO ordinal scale score of 3, 4 or 5 at baseline&#xD;
&#xD;
          4. Male or non-pregnant female adult ≥18 years of age at time of enrolment.&#xD;
&#xD;
          5. Subject (or legally authorized representative (LAR)) provides written informed consent&#xD;
             prior to initiation of any study procedures.&#xD;
&#xD;
          6. Understands and agrees to comply with planned study procedures.&#xD;
&#xD;
          7. Illness of any duration&#xD;
&#xD;
          8. Women of childbearing potential must have a negative blood pregnancy test at the&#xD;
             screening/baseline visit (Day 1) and agree to use a double method of birth control&#xD;
             through 30 days after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intubated and mechanically ventilated at baseline&#xD;
&#xD;
          2. Receiving extracorporeal membrane oxygenation (ECMO) at baseline&#xD;
&#xD;
          3. Severe organ dysfunction (SOFA score &gt; 10)&#xD;
&#xD;
          4. Patient or LAR unable to provide written informed consent&#xD;
&#xD;
          5. ALT/AST &gt; 3 times the upper limit of normal or serum bilirubin &gt; 1.5 times the upper&#xD;
             limit of normal&#xD;
&#xD;
          6. Estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease&#xD;
             (MDRD) formula &lt; 30 mL/min/1.73 m^2 or on dialysis&#xD;
&#xD;
          7. Pregnancy or breast feeding.&#xD;
&#xD;
          8. Anticipated transfer to another hospital which is not a study site within 72 hours.&#xD;
&#xD;
          9. Allergy to any study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Streinu Cercel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Infectious Diseases, Bucharest, Romania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Infectious Diseases- Prof. Dr. Matei Balş</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <results_first_submitted>March 14, 2022</results_first_submitted>
  <results_first_submitted_qc>March 30, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2022</results_first_posted>
  <last_update_submitted>April 12, 2022</last_update_submitted>
  <last_update_submitted_qc>April 12, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxemia</keyword>
  <keyword>Hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trans-sodium crocetinate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT04573322/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Phase 1 lead-in was conducted; however, the study was completed prior to initiation of Phase 2. Therefore, only data are reported for the lead-in phase, as no data were collected for Phase 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lead-in 0.25 mg/kg</title>
          <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="P2">
          <title>Lead-in 0.50 mg/kg</title>
          <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="P3">
          <title>Lead-in 1.0 mg/kg</title>
          <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="P4">
          <title>Lead-in 1.5 mg/kg</title>
          <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Phase 1 lead-in was conducted; however, the study was completed prior to initiation of Phase 2. Therefore, only data are reported for the lead-in phase, as no data were collected for Phase 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Lead-in 0.25 mg/kg</title>
          <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="B2">
          <title>Lead-in 0.50 mg/kg</title>
          <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="B3">
          <title>Lead-in 1.0 mg/kg</title>
          <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="B4">
          <title>Lead-in 1.5 mg/kg</title>
          <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.50" spread="18.87"/>
                    <measurement group_id="B2" value="60.83" spread="16.04"/>
                    <measurement group_id="B3" value="54.43" spread="8.16"/>
                    <measurement group_id="B4" value="57.50" spread="8.89"/>
                    <measurement group_id="B5" value="56.00" spread="13.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</title>
        <description>Lead-in phase: Overall summary of subjects with TEAEs</description>
        <time_frame>Up to 70 days post-study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lead-in 0.25 mg/kg</title>
            <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O2">
            <title>Lead-in 0.50 mg/kg</title>
            <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O3">
            <title>Lead-in 1.0 mg/kg</title>
            <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O4">
            <title>Lead-in 1.5 mg/kg</title>
            <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</title>
          <description>Lead-in phase: Overall summary of subjects with TEAEs</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with any Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with any TEAE of DLT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with any TEAE Resulting in Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with any TEAE Leading to Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with any TEAE Leading to Study Drug Interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with any TEAE with CTCAE Grade 3 or 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Recovery Through Day 28</title>
        <description>Lead-in phase: Time to achieve (and maintain through Day 28) a World Health Organization (WHO) ordinal COVID-19 severity scale score of 1, 2 or 3 with a minimum 1-point improvement from baseline. The scale assesses clinical status and the range is 0-8, as follows:&#xD;
0. Uninfected - No clinical or virological evidence of infection&#xD;
Ambulatory - No limitation of activities&#xD;
Ambulatory - Limitation of activities&#xD;
Hospitalized, Mild Disease - Hospitalized, no oxygen therapy&#xD;
Hospitalized, Mild Disease - Oxygen by mask or nasal prongs&#xD;
Hospitalized Severe Disease - Non-invasive ventilation or high-low oxygen&#xD;
Hospitalized Severe Disease - Intubation and mechanical ventilation&#xD;
Hospitalized Severe Disease - Ventilation + additional organ support (pressors, Renal Replacement Therapy (RRT), Extracorporeal Membrane Oxygenation (ECMO)&#xD;
Dead - Death</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lead-in 0.25 mg/kg</title>
            <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O2">
            <title>Lead-in 0.50 mg/kg</title>
            <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O3">
            <title>Lead-in 1.0 mg/kg</title>
            <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O4">
            <title>Lead-in 1.5 mg/kg</title>
            <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery Through Day 28</title>
          <description>Lead-in phase: Time to achieve (and maintain through Day 28) a World Health Organization (WHO) ordinal COVID-19 severity scale score of 1, 2 or 3 with a minimum 1-point improvement from baseline. The scale assesses clinical status and the range is 0-8, as follows:&#xD;
0. Uninfected - No clinical or virological evidence of infection&#xD;
Ambulatory - No limitation of activities&#xD;
Ambulatory - Limitation of activities&#xD;
Hospitalized, Mild Disease - Hospitalized, no oxygen therapy&#xD;
Hospitalized, Mild Disease - Oxygen by mask or nasal prongs&#xD;
Hospitalized Severe Disease - Non-invasive ventilation or high-low oxygen&#xD;
Hospitalized Severe Disease - Intubation and mechanical ventilation&#xD;
Hospitalized Severe Disease - Ventilation + additional organ support (pressors, Renal Replacement Therapy (RRT), Extracorporeal Membrane Oxygenation (ECMO)&#xD;
Dead - Death</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.33" spread="11.54"/>
                    <measurement group_id="O2" value="13.67" spread="8.43"/>
                    <measurement group_id="O3" value="7.71" spread="4.31"/>
                    <measurement group_id="O4" value="7.50" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WHO Ordinal Severity Scale as a Categorical Improvement or Worsening</title>
        <description>Lead-in phase: Number and percentage of patients by WHO Severity Scale change from baseline through Day 7&#xD;
World Health Organization (WHO) Ordinal Severity Scale&#xD;
Not hospitalized, no limitations on activities&#xD;
Not hospitalized, limitation on activities&#xD;
Hospitalized, no requiring supplemental oxygen&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, on non-invasive ventilation or high flow O2&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Death</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lead-in 0.25 mg/kg</title>
            <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O2">
            <title>Lead-in 0.50 mg/kg</title>
            <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O3">
            <title>Lead-in 1.0 mg/kg</title>
            <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O4">
            <title>Lead-in 1.5 mg/kg</title>
            <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WHO Ordinal Severity Scale as a Categorical Improvement or Worsening</title>
          <description>Lead-in phase: Number and percentage of patients by WHO Severity Scale change from baseline through Day 7&#xD;
World Health Organization (WHO) Ordinal Severity Scale&#xD;
Not hospitalized, no limitations on activities&#xD;
Not hospitalized, limitation on activities&#xD;
Hospitalized, no requiring supplemental oxygen&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, on non-invasive ventilation or high flow O2&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Point Worse from Day 1 to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change from Day 1 to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Point Improvement from Day 1 to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Data Collected on Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation - Ventilator Free Days</title>
        <description>Lead-in phase: Ventilator free days in the first 28 days (to day 29).</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lead-in 0.25 mg/kg</title>
            <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O2">
            <title>Lead-in 0.50 mg/kg</title>
            <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O3">
            <title>Lead-in 1.0 mg/kg</title>
            <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O4">
            <title>Lead-in 1.5 mg/kg</title>
            <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation - Ventilator Free Days</title>
          <description>Lead-in phase: Ventilator free days in the first 28 days (to day 29).</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="6.05"/>
                    <measurement group_id="O2" value="16.00" spread="5.33"/>
                    <measurement group_id="O3" value="15.43" spread="7.28"/>
                    <measurement group_id="O4" value="19.83" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Lead-in phase: Days of treatment during the inpatient period</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lead-in 0.25 mg/kg</title>
            <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O2">
            <title>Lead-in 0.50 mg/kg</title>
            <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O3">
            <title>Lead-in 1.0 mg/kg</title>
            <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O4">
            <title>Lead-in 1.5 mg/kg</title>
            <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Lead-in phase: Days of treatment during the inpatient period</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="2.66"/>
                    <measurement group_id="O2" value="9.67" spread="2.88"/>
                    <measurement group_id="O3" value="8.57" spread="3.78"/>
                    <measurement group_id="O4" value="8.00" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation - Time to Return to Baseline</title>
        <description>Lead-in phase: Time to return to room air or baseline oxygen requirement</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lead-in 0.25 mg/kg</title>
            <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O2">
            <title>Lead-in 0.50 mg/kg</title>
            <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O3">
            <title>Lead-in 1.0 mg/kg</title>
            <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O4">
            <title>Lead-in 1.5 mg/kg</title>
            <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation - Time to Return to Baseline</title>
          <description>Lead-in phase: Time to return to room air or baseline oxygen requirement</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" spread="5.68"/>
                    <measurement group_id="O2" value="18.92" spread="18.25"/>
                    <measurement group_id="O3" value="11.79" spread="7.47"/>
                    <measurement group_id="O4" value="5.50" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation - Pulse Oximetry</title>
        <description>Lead-in phase: Blood oxygenation by recorded continuous pulse oximetry (SpO2:FiO2 ratio)</description>
        <time_frame>Baseline through Day 10</time_frame>
        <population>There are some time points where data were not collected and, for the later timepoints, subjects discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Lead-in 0.25 mg/kg</title>
            <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O2">
            <title>Lead-in 0.50 mg/kg</title>
            <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O3">
            <title>Lead-in 1.0 mg/kg</title>
            <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
          <group group_id="O4">
            <title>Lead-in 1.5 mg/kg</title>
            <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation - Pulse Oximetry</title>
          <description>Lead-in phase: Blood oxygenation by recorded continuous pulse oximetry (SpO2:FiO2 ratio)</description>
          <population>There are some time points where data were not collected and, for the later timepoints, subjects discontinued.</population>
          <units>SpO2:FiO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre First Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.83" spread="73.80"/>
                    <measurement group_id="O2" value="164.33" spread="64.91"/>
                    <measurement group_id="O3" value="183.97" spread="41.34"/>
                    <measurement group_id="O4" value="255.03" spread="57.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.83" spread="73.80"/>
                    <measurement group_id="O2" value="164.33" spread="64.91"/>
                    <measurement group_id="O3" value="183.97" spread="41.34"/>
                    <measurement group_id="O4" value="255.03" spread="57.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 Minute Post Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.22" spread="74.87"/>
                    <measurement group_id="O2" value="163.33" spread="61.87"/>
                    <measurement group_id="O3" value="189.16" spread="46.07"/>
                    <measurement group_id="O4" value="255.33" spread="57.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 10 Minutes Post Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.22" spread="74.90"/>
                    <measurement group_id="O2" value="164.87" spread="63.89"/>
                    <measurement group_id="O3" value="188.37" spread="46.00"/>
                    <measurement group_id="O4" value="255.15" spread="55.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 30 Minutes Post Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.73" spread="76.50"/>
                    <measurement group_id="O2" value="165.67" spread="63.91"/>
                    <measurement group_id="O3" value="187.81" spread="45.89"/>
                    <measurement group_id="O4" value="256.07" spread="56.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.5 Hours Post Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.22" spread="76.78"/>
                    <measurement group_id="O2" value="164.32" spread="62.38"/>
                    <measurement group_id="O3" value="187.89" spread="45.01"/>
                    <measurement group_id="O4" value="255.65" spread="54.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 3 Hours Post Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.82" spread="78.20"/>
                    <measurement group_id="O2" value="165.20" spread="62.96"/>
                    <measurement group_id="O3" value="189.80" spread="46.50"/>
                    <measurement group_id="O4" value="256.67" spread="55.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.98" spread="87.49"/>
                    <measurement group_id="O2" value="165.35" spread="63.48"/>
                    <measurement group_id="O3" value="188.84" spread="45.79"/>
                    <measurement group_id="O4" value="255.95" spread="56.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.23" spread="89.57"/>
                    <measurement group_id="O2" value="166.17" spread="61.57"/>
                    <measurement group_id="O3" value="189.86" spread="43.19"/>
                    <measurement group_id="O4" value="255.72" spread="54.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.47" spread="88.97"/>
                    <measurement group_id="O2" value="165.83" spread="64.40"/>
                    <measurement group_id="O3" value="189.40" spread="44.72"/>
                    <measurement group_id="O4" value="255.78" spread="55.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.90" spread="118.47"/>
                    <measurement group_id="O2" value="165.32" spread="63.52"/>
                    <measurement group_id="O3" value="207.80" spread="30.76"/>
                    <measurement group_id="O4" value="275.20" spread="51.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 1 Minute Post Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.90" spread="118.00"/>
                    <measurement group_id="O2" value="165.98" spread="63.00"/>
                    <measurement group_id="O3" value="202.00" spread="33.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.17" spread="147.94"/>
                    <measurement group_id="O2" value="172.12" spread="93.68"/>
                    <measurement group_id="O3" value="201.52" spread="39.10"/>
                    <measurement group_id="O4" value="267.90" spread="58.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.43" spread="146.10"/>
                    <measurement group_id="O2" value="173.68" spread="94.74"/>
                    <measurement group_id="O3" value="204.42" spread="49.32"/>
                    <measurement group_id="O4" value="267.57" spread="56.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.40" spread="147.32"/>
                    <measurement group_id="O2" value="174.33" spread="96.09"/>
                    <measurement group_id="O3" value="215.25" spread="39.84"/>
                    <measurement group_id="O4" value="266.48" spread="55.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.12" spread="121.86"/>
                    <measurement group_id="O2" value="174.08" spread="95.67"/>
                    <measurement group_id="O3" value="247.23" spread="65.92"/>
                    <measurement group_id="O4" value="270.38" spread="71.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 1 Minute Post Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.57" spread="121.88"/>
                    <measurement group_id="O2" value="174.08" spread="95.67"/>
                    <measurement group_id="O3" value="245.97" spread="71.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.47" spread="121.09"/>
                    <measurement group_id="O2" value="174.50" spread="93.34"/>
                    <measurement group_id="O3" value="248.12" spread="66.38"/>
                    <measurement group_id="O4" value="271.20" spread="71.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.68" spread="120.38"/>
                    <measurement group_id="O2" value="175.05" spread="95.16"/>
                    <measurement group_id="O3" value="254.85" spread="60.32"/>
                    <measurement group_id="O4" value="271.70" spread="72.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.48" spread="121.26"/>
                    <measurement group_id="O2" value="175.18" spread="95.25"/>
                    <measurement group_id="O3" value="259.87" spread="52.29"/>
                    <measurement group_id="O4" value="279.78" spread="67.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.20" spread="147.31"/>
                    <measurement group_id="O2" value="179.77" spread="95.57"/>
                    <measurement group_id="O3" value="286.12" spread="95.93"/>
                    <measurement group_id="O4" value="321.28" spread="69.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.03" spread="145.69"/>
                    <measurement group_id="O2" value="176.32" spread="87.93"/>
                    <measurement group_id="O3" value="264.70" spread="51.29"/>
                    <measurement group_id="O4" value="322.13" spread="71.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.78" spread="144.73"/>
                    <measurement group_id="O2" value="176.32" spread="87.96"/>
                    <measurement group_id="O3" value="266.77" spread="53.24"/>
                    <measurement group_id="O4" value="320.35" spread="70.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.85" spread="143.53"/>
                    <measurement group_id="O2" value="177.28" spread="89.45"/>
                    <measurement group_id="O3" value="302.93" spread="91.27"/>
                    <measurement group_id="O4" value="335.45" spread="59.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.23" spread="151.89"/>
                    <measurement group_id="O2" value="176.55" spread="90.15"/>
                    <measurement group_id="O3" value="301.43" spread="91.31"/>
                    <measurement group_id="O4" value="343.87" spread="57.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.03" spread="152.74"/>
                    <measurement group_id="O2" value="175.73" spread="88.43"/>
                    <measurement group_id="O3" value="316.25" spread="85.00"/>
                    <measurement group_id="O4" value="344.85" spread="56.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.75" spread="151.69"/>
                    <measurement group_id="O2" value="176.88" spread="89.80"/>
                    <measurement group_id="O3" value="314.82" spread="82.17"/>
                    <measurement group_id="O4" value="355.35" spread="63.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.23" spread="151.77"/>
                    <measurement group_id="O2" value="184.67" spread="102.13"/>
                    <measurement group_id="O3" value="297.18" spread="45.15"/>
                    <measurement group_id="O4" value="348.40" spread="75.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.96" spread="175.22"/>
                    <measurement group_id="O2" value="189.23" spread="108.10"/>
                    <measurement group_id="O3" value="343.86" spread="68.07"/>
                    <measurement group_id="O4" value="341.25" spread="87.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.55" spread="237.38"/>
                    <measurement group_id="O2" value="232.48" spread="138.43"/>
                    <measurement group_id="O3" value="322.44" spread="29.39"/>
                    <measurement group_id="O4" value="340.63" spread="90.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298.80" spread="230.66"/>
                    <measurement group_id="O2" value="233.93" spread="140.79"/>
                    <measurement group_id="O3" value="322.28" spread="27.37"/>
                    <measurement group_id="O4" value="356.63" spread="111.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.90" spread="233.06"/>
                    <measurement group_id="O2" value="232.73" spread="138.10"/>
                    <measurement group_id="O3" value="343.38" spread="69.97"/>
                    <measurement group_id="O4" value="415.68" spread="95.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.05" spread="99.73"/>
                    <measurement group_id="O2" value="236.05" spread="179.16"/>
                    <measurement group_id="O3" value="341.35" spread="67.98"/>
                    <measurement group_id="O4" value="433.48" spread="79.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.85" spread="123.67"/>
                    <measurement group_id="O2" value="232.17" spread="212.20"/>
                    <measurement group_id="O3" value="371.78" spread="57.66"/>
                    <measurement group_id="O4" value="402.50" spread="115.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.15" spread="124.66"/>
                    <measurement group_id="O2" value="223.37" spread="217.08"/>
                    <measurement group_id="O3" value="340.00" spread="11.55"/>
                    <measurement group_id="O4" value="403.43" spread="113.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.60" spread="122.61"/>
                    <measurement group_id="O2" value="226.13" spread="214.31"/>
                    <measurement group_id="O3" value="401.85" spread="70.12"/>
                    <measurement group_id="O4" value="411.63" spread="91.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.37" spread="164.58"/>
                    <measurement group_id="O2" value="187.60" spread="156.67"/>
                    <measurement group_id="O3" value="378.26" spread="85.71"/>
                    <measurement group_id="O4" value="425.80" spread="81.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.30" spread="121.62"/>
                    <measurement group_id="O2" value="233.23" spread="206.81"/>
                    <measurement group_id="O3" value="422.60" spread="59.76"/>
                    <measurement group_id="O4" value="306.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.55" spread="122.40"/>
                    <measurement group_id="O2" value="248.03" spread="193.52"/>
                    <measurement group_id="O3" value="385.00" spread="75.75"/>
                    <measurement group_id="O4" value="306.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.70" spread="126.85"/>
                    <measurement group_id="O2" value="246.00" spread="191.24"/>
                    <measurement group_id="O3" value="410.15" spread="79.97"/>
                    <measurement group_id="O4" value="461.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.75" spread="229.60"/>
                    <measurement group_id="O2" value="221.45" spread="166.65"/>
                    <measurement group_id="O3" value="395.48" spread="79.54"/>
                    <measurement group_id="O4" value="461.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.25" spread="234.55"/>
                    <measurement group_id="O2" value="248.47" spread="189.04"/>
                    <measurement group_id="O3" value="398.35" spread="96.66"/>
                    <measurement group_id="O4" value="457.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.35" spread="231.58"/>
                    <measurement group_id="O2" value="149.95" spread="18.88"/>
                    <measurement group_id="O3" value="395.95" spread="93.27"/>
                    <measurement group_id="O4" value="457.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.70" spread="227.26"/>
                    <measurement group_id="O2" value="158.10" spread="28.43"/>
                    <measurement group_id="O3" value="471.40" spread="0.00"/>
                    <measurement group_id="O4" value="457.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, Prior to Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.80" spread="130.81"/>
                    <measurement group_id="O2" value="154.67" spread="23.93"/>
                    <measurement group_id="O3" value="395.03" spread="82.81"/>
                    <measurement group_id="O4" value="457.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, Prior to Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.50" spread="129.82"/>
                    <measurement group_id="O2" value="159.20" spread="31.96"/>
                    <measurement group_id="O3" value="394.30" spread="95.60"/>
                    <measurement group_id="O4" value="452.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, Prior to Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.70"/>
                    <measurement group_id="O2" value="159.90" spread="30.97"/>
                    <measurement group_id="O3" value="469.05" spread="3.32"/>
                    <measurement group_id="O4" value="461.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, Prior to Dose 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.70"/>
                    <measurement group_id="O2" value="158.50" spread="32.95"/>
                    <measurement group_id="O3" value="469.05" spread="3.32"/>
                    <measurement group_id="O4" value="466.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected for up to 70 days from the start of study drug administration through the 60-day follow-up visit (+10d).</time_frame>
      <desc>Phase 1 lead-in was conducted; however, the study was completed prior to initiation of Phase 2. Therefore, only data are reported for the lead-in phase, as no data were collected for Phase 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lead-in 0.25 mg/kg</title>
          <description>0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="E2">
          <title>Lead-in 0.50 mg/kg</title>
          <description>0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="E3">
          <title>Lead-in 1.0 mg/kg</title>
          <description>1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
        <group group_id="E4">
          <title>Lead-in 1.5 mg/kg</title>
          <description>1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days&#xD;
Trans Sodium Crocetinate: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Congestive Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive Cerumen Production</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hernial Eventration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatocellular Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Superinfection Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT Prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chris Galloway, MD (Chief Medical Officer)</name_or_title>
      <organization>Diffusion Pharmaceuticals</organization>
      <phone>(434) 220-0718</phone>
      <email>cgalloway@diffusionpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

